Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients.
Association of multiple sclerosis susceptibility variants and early attack location in the CNS.
Dimethyl fumarate (Tecfidera) for multiple sclerosis.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
The natural course of clinically isolated syndrome in pediatric patients.
Genzyme’s Lemtrada® approved in Mexico for treatment of multiple sclerosis
Integration of MicroRNA Databases to Study MicroRNAs Associated with Multiple Sclerosis.
Laquinimod
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
Genzyme to Resubmit LemtradaTM Application for FDA Review
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study.
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry.
Mast cells: an expanding pathophysiological role from allergy to other disorders.
A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city.
European ancestry predominates in neuromyelitis optica and multiple sclerosis patients from Brazil.
Pages
« first
‹ previous
…
164
165
166
167
168
169
170
171
172
…
next ›
last »